专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

51. 发明申请

WO2017156625A1 CALCIUM BINDING PROTEIN, SPERMATID SPECIFIC 1, AS A BIOMARKER FOR DIAGNOSIS OR TREATMENT OF STRESS 审中-公开
标题翻译：钙结合蛋白，SPECTMATID特异性1，作为诊断或治疗压力的生物标记物
公开(公告)号：WO2017156625A1
公开(公告)日：2017-09-21
申请号：PCT/CA2017/050331
申请日：2017-03-14
申请人： THE GOVERNORS OF THE UNIVERSITY OF ALBERTA
发明人： BEFUS, Dean , RITZ, Thomas , ST. LAURENT, Chris , ST. LAURENT, Katherine
IPC分类号： G01N33/53 , G01N33/48 , G01N33/543
CPC分类号： G01N33/5308 , G01N33/5091 , G01N33/6893 , G01N2333/4727 , G01N2800/301 , G16B25/00
摘要： A method of determining risk of stress in a subject involves determining in a biological sample, the level of one or more forms of calcium binding protein spermatid specific 1 protein, wherein the one or more forms comprise one or more of 12 kDa, 15 kDa, 18 kDa, 20 kDa, 27 kDa, 33 kDa, 55 kDa, or 90 kDa forms; comparing the level of the one or more forms in the sample with the level of the one or more forms in a normal control; determining whether the subject has risk of stress in accordance with the result; wherein a difference in the level of the one or more forms relative to the level of the normal control, is indicative of stress or responsiveness to stressful stimuli; and treating the subject with a stress management program that involves using one or more forms of 12 kDa, 15 kDa, 18 kDa, 20 kDa, 27 kDa, 33 kDa, 55 kDa, or 90 kDa forms as therapeutic targets.
摘要翻译：测定受试者中压力风险的方法涉及确定生物样品中一种或多种形式的钙结合蛋白精子细胞特异性蛋白质的水平，其中所述一种或多种形式包含一种或多种形式的更多12kDa，15kDa，18kDa，20kDa，27kDa，33kDa，55kDa或90kDa形式; 将样本中的一种或多种形式的水平与正常对照中的一种或多种形式的水平进行比较; 根据结果确定受试者是否有压力风险; 其中一种或多种形式的水平相对于正常对照的水平的差异指示对压力刺激的应激或应答性; 并且用包括使用一种或多种形式的12kDa，15kDa，18kDa，20kDa，27kDa，33kDa，55kDa或90kDa形式作为治疗靶点的压力管理程序来治疗受试者。

52. 发明申请

WO2017079653A3 METHODS OF DETECTING INFLAMMATORY MARKERS AND TREATING INFLAMMATORY CONDITIONS IN COMPANION ANIMALS 审中-公开
标题翻译：在同伴动物中检测炎症标记物和治疗炎症状况的方法
公开(公告)号：WO2017079653A3
公开(公告)日：2017-06-15
申请号：PCT/US2016060674
申请日：2016-11-04
申请人： VETICA LABS INC
发明人： ESTRUCH JUAN , HANSEN GENEVIEVE
IPC分类号： G01N33/53 , G01N33/563 , G01N33/564 , G01N33/569 , G01N33/58
CPC分类号： G01N33/6893 , A23K50/40 , C07K16/12 , C07K16/18 , C07K16/28 , C07K16/2839 , G01N33/5005 , G01N33/564 , G01N33/56911 , G01N33/6854 , G01N2333/195 , G01N2333/4727 , G01N2333/4737 , G01N2333/70546 , G01N2333/79 , G01N2800/06 , G01N2800/24
摘要： The present invention provides methods and systems to accurately detect and measure levels of endogenous antibodies, for examples endogenous IgA, to particular antigens in a biological sample from a companion animal, which is useful to diagnose inflammatory conditions, including bowel disease (IBD), in companion animals, e.g., dogs or cats. Such methods and systems identify whether a sample from the patient is associated with an inflammatory condition, by using non-invasive means, thus conveniently providing information useful for guiding treatment decisions.
摘要翻译：本发明提供了用于准确检测和测量来自伴侣动物的生物样品中的特定抗原的内源性抗体（例如内源性IgA）水平的方法和系统，所述生物样品可用于诊断炎性病症，包括肠病（IBD）伴侣动物，例如狗或猫。这样的方法和系统通过使用非侵入性手段识别来自患者的样本是否与炎性病症相关联，从而方便地提供对指导治疗决定有用的信息。

53. 发明申请

WO2016179706A1 BIOSENSORS AND METHODS FOR DETECTION OF LYSOPHOSPHATIDIC ACID FOR SIGNALING OF OVARIAN CANCER 审中-公开
标题翻译：用于检测卵巢癌的信号的生物传感器和方法
公开(公告)号：WO2016179706A1
公开(公告)日：2016-11-17
申请号：PCT/CA2016/050545
申请日：2016-05-13
申请人： DE LA FRANIER, Brian , THOMPSON, Michael
发明人： DE LA FRANIER, Brian , THOMPSON, Michael
IPC分类号： C07F7/12 , G01N33/53
CPC分类号： G01N33/57449 , C07F7/12 , G01N33/57442 , G01N33/57488 , G01N33/6872 , G01N33/92 , G01N2333/4703 , G01N2333/4712 , G01N2333/4727 , G01N2405/04 , G01N2610/00
摘要： The present disclosure relates to biosensors, kits and methods for detecting and/or quantifying lysophosphatidic acid (LPA) in a liquid sample such as a serum sample from a subject. The present disclosure also relates to linker compounds that are useful, for example, in the biosensors, kits and methods of the present disclosure and to methods for preparing a biosensor for detecting and/or quantifying lysophosphatidic acid (LPA) in a liquid sample.
摘要翻译：本公开涉及用于检测和/或定量液体样品（例如来自受试者的血清样品）中的溶血磷脂酸（LPA）的生物传感器，试剂盒和方法。本公开还涉及可用于例如本发明的生物传感器，试剂盒和方法中的接头化合物以及制备用于检测和/或定量液体样品中溶血磷脂酸（LPA）的生物传感器的方法。

54. 发明申请

WO2016133774A1 DIAGNOSTIC REAGENTS AND METHODS SPECIFIC TO INNER EAR DISORDERS 审中-公开
标题翻译：诊断试剂和特异性内分泌疾病的方法
公开(公告)号：WO2016133774A1
公开(公告)日：2016-08-25
申请号：PCT/US2016/017476
申请日：2016-02-11
申请人： THE UNIVERSITY OF CONNECTICUT
发明人： PARHAM, Kourosh
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N2333/47 , G01N2333/4727 , G01N2800/14
摘要： Described herein are compositions and methods for the detection of inner ear disorders such as balance disorders and hearing disorders resulting from acoustic injury, exposure to ototoxins, head trauma or viral illness. Specifically, otolin-1 and prestin have been verified as inner-ear specific biomarkers suitable for the detection of inner ear disorders.
摘要翻译：本文描述了用于检测内耳障碍的组合物和方法，例如由声学损伤，暴露于耳毒素，头部创伤或病毒性疾病引起的平衡障碍和听觉障碍。具体来说，otolin-1和prestin已被证实为适合于检测内耳障碍的内耳特异性生物标志物。

55. 发明申请

WO2016008949A1 IN VIVO DETECTION OF PROTEINS INTERACTION BASED ON ADENYLATE CYCLASE HYBRID SYSTEM 审中-公开
标题翻译：基于ADENYLATE CYCLASE HYBRID SYSTEM的蛋白质相互作用检测
公开(公告)号：WO2016008949A1
公开(公告)日：2016-01-21
申请号：PCT/EP2015/066207
申请日：2015-07-15
申请人： INSTITUT PASTEUR , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
发明人： LADANT, Daniel , DAVI, Marilyne
IPC分类号： C12N15/10 , G01N33/68
CPC分类号： C12N15/1055 , C07K14/4728 , C12N9/88 , C12Y406/01001 , G01N33/573 , G01N2333/4727 , G01N2333/988
摘要： The present invention relates to a method to detect the interaction between a target ligand and a moiety of interest using an adenylate cyclase enzyme (AC) and calmodulin (CaM) as interacting partners, said method comprising: i) expressing in a suitable host cell: (a) a low number of molecules of a first chimeric polypeptide containing AC, and (b) a low number of molecules of a second chimeric polypeptide containing CaM, wherein said AC in said first chimeric polypeptide and/or said CaM in said second chimeric polypeptide has decreased affinity for its interacting partner, wherein said AC in said first chimeric polypeptide is fused to a moiety of interest and said CaM in said second chimeric polypeptide is fused to a target ligand, or conversely, and wherein, when said moiety of interest and said target ligand interact, said AC is activated, and ii) detecting the activation of said AC. The present inventors herein show that only one AC/CaM complex per cell is sufficient to confer a selectable trait to the host cell. Unexpectedly, even less than one AC/CaM complex per cell can be sufficient to confer a selectable trait to the host cell. This surprising result confers a very high sensitivity, that is helpful for screening high affinity interactions, such as antigen-antibody interactions. Moreover, the bw expression of the chimeric proteins that is achieved in the present invention allows to characterize toxic moieties, what was not possible before.
摘要翻译：本发明涉及使用腺苷酸环化酶（AC）和钙调蛋白（CaM）作为相互作用的伴侣来检测目标配体和感兴趣部分之间的相互作用的方法，所述方法包括：i）在合适的宿主细胞中表达：（a）少量含有AC的第一嵌合多肽的分子，和（b）少量含有CaM的第二嵌合多肽的分子，其中所述第一嵌合多肽中的所述AC和/或所述第二嵌合多肽中的所述CaM 多肽对其相互作用的配偶体具有降低的亲和力，其中所述第一嵌合多肽中的所述AC与感兴趣部分融合，并且所述第二嵌合多肽中的所述CaM与靶配体融合，或相反地并且其中当所述感兴趣的部分并且所述靶配体相互作用，所述AC被激活，和ii）检测所述AC的活化。本发明人在此显示每个细胞仅一个AC / CaM复合物足以赋予宿主细胞可选择的性状。意外的是，每个细胞甚至少于一个AC / CaM复合物可足以赋予宿主细胞可选择的特征。这种惊人的结果赋予了非常高的灵敏度，这有助于筛选高亲和力相互作用，例如抗原 - 抗体相互作用。此外，在本发明中实现的嵌合蛋白的bw表达允许表征有毒部分，以前是不可能的。

56. 发明申请

WO2015182218A1 膵癌判定方法审中-公开
标题翻译：胰腺癌确定方法
公开(公告)号：WO2015182218A1
公开(公告)日：2015-12-03
申请号：PCT/JP2015/057673
申请日：2015-03-16
申请人：オリンパス株式会社
发明人：中田　真理
IPC分类号： G01N33/68 , C12Q1/04 , G01N33/50
CPC分类号： G01N33/57438 , C12Q1/04 , G01N33/50 , G01N33/68 , G01N2333/4727 , G01N2333/70596 , G01N2400/00
摘要：　本発明の膵癌判定方法は、被験者における膵癌の判定を行う膵癌判定方法であって、前記被験者の十二指腸液中の第一のマーカーの濃度を測定する第一工程と、前記被験者の血液サンプル中の第二のマーカーの濃度を測定する第二工程と、前記第一マーカーの濃度が第一のカットオフ値以上であるか否か、および前記第二マーカーの濃度が第二のカットオフ値以上であるか否かに基づいて、前記被験者における膵癌の存在と前記膵癌の進行度との少なくとも一方を判定する第三工程と、を備える。
摘要翻译：提供一种胰腺癌测定方法，其中确定受试者的胰腺癌，其包括：用于测量受试者的十二指肠液中的第一标记物的浓度的第一步骤; 用于测量受试者血液样本中第二标记物浓度的第二步骤; 以及第三步骤，基于第一标记物的浓度是否不低于第一临界值，确定受试者胰腺癌的存在和/或胰腺进展的阶段，以及是否或不是第二标记物的浓度不低于第二截止值。

57. 发明申请

WO2015177211A1 METHOD FOR DETERMINATION OF A PROTEIN 审中-公开
标题翻译：测定蛋白质的方法
公开(公告)号：WO2015177211A1
公开(公告)日：2015-11-26
申请号：PCT/EP2015/061111
申请日：2015-05-20
申请人： BÜHLMANN LABORATORIES AG
发明人： WEBER, Jakob , ÜBERSCHLAG, Marie-Eve , PRICA, Marianne , JERMANN, Thomas
IPC分类号： G01N33/543
CPC分类号： G01N33/6827 , G01N33/54393 , G01N2333/4727
摘要： The present invention concerns a method for determining the concentration of a protein in a gastrointestinal (GI) tract sample taken from a human or an animal. The present invention is characterized by the feature that a dilution of the sample in the buffered aqueous extraction medium in a range of 1 : 100 to 1 : 10,000 is obtained. The present invention leads to a significant improvement of the technical situation, and provides a simple, sensitive and specific determination tool of proteins in GI tract samples. The determination of proteins, e.g. calprotectin, elastases or hemoglobin, in GI tract samples leads to more accurate and reproducible results.
摘要翻译：本发明涉及一种用于测定取自人或动物的胃肠道（GI）道样品中蛋白质浓度的方法。本发明的特征在于，将缓冲的含水萃取介质中的样品稀释在1：100至1：10,000的范围内。本发明导致技术状况的显着改善，并提供了胃肠道样品中蛋白质的简单，灵敏和具体的测定工具。蛋白质的测定，例如胃肠道样品中的钙卫蛋白，弹性蛋白酶或血红蛋白导致更准确和可重复的结果。

58. 发明申请

WO2015158652A2 NEW BIOMARKERS FOR METASTATIC BREAST CANCER 审中-公开
标题翻译：新生物标志物用于分类乳腺癌
公开(公告)号：WO2015158652A2
公开(公告)日：2015-10-22
申请号：PCT/EP2015/057946
申请日：2015-04-13
申请人： DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS
发明人： BURWINKEL, Barbara , YANG, Rongxi , PENG, Cike , SCHNEEWEISS, Andreas
IPC分类号： G01N33/574
CPC分类号： G01N33/57415 , G01N2333/4727 , G01N2333/705 , G01N2400/40 , G01N2800/52
摘要： The present invention pertains to a new method for the diagnosis, prognosis, stratification and/or monitoring of a therapy, of breast cancer in a patient. The method is based on the use of hyaluronic acid and S100P as combined biomarkers in the plasma of breast cancer patients. The new biomarkers of the invention allow diagnosing and even stratifying of breast cancer, in particular metastatic breast cancer. The method provides an interesting alternative to present procedures such as the analysis of the circulating tumor cells (CTC) status. The biomarkers of the invention furthermore allow to monitor therapy success of breast cancer patients and to estimate a patient's prognosis.
摘要翻译：本发明涉及用于患者的乳腺癌的治疗的诊断，预后，分层和/或监测的新方法。该方法基于在乳腺癌患者血浆中使用透明质酸和S100P作为组合生物标志物。本发明的新生物标志物允许诊断甚至分层乳腺癌，特别是转移性乳腺癌。该方法提供了一个有趣的替代方案，例如循环肿瘤细胞（CTC）状态的分析。本发明的生物标志物还允许监测乳腺癌患者的治疗成功并估计患者的预后。

59. 发明申请

WO2015036599A1 MUTANT CALRETICULIN FOR THE DIAGNOSIS OF MYELOID MALIGNANCIES 审中-公开
标题翻译： MUTANT CALRETICULIN用于诊断MYELOID MALIGNANCIES
公开(公告)号：WO2015036599A1
公开(公告)日：2015-03-19
申请号：PCT/EP2014/069638
申请日：2014-09-15
申请人： CEMM - FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GMBH
发明人： KRALOVICS, Robert , KLAMPFL, Thorsten , GISSLINGER, Heinz
IPC分类号： C07K14/47 , C12Q1/68
CPC分类号： C12Q1/6886 , A61K39/0005 , C07K14/4728 , C07K16/18 , C07K2317/76 , C12N15/113 , C12N2310/14 , C12Q2600/156 , C12Q2600/172 , G01N33/57426 , G01N2333/47 , G01N2333/4727
摘要： The present invention relates to a method for diagnosing myeloid malignancy comprising determining the presence of a mutant allele of the calreticulin gene. Also genomic sequences, cDNA sequences, mRNA sequences and protein sequences of the mutant calreticulin are subject of the present invention. Further, the invention relates to medical uses of inhibitors of mutant calreticulin.
摘要翻译：本发明涉及一种诊断骨髓恶性肿瘤的方法，包括确定钙网蛋白基因的突变等位基因的存在。突变体钙网蛋白的基因组序列，cDNA序列，mRNA序列和蛋白质序列也是本发明的主题。此外，本发明涉及突变钙网蛋白抑制剂的医学用途。

60. 发明申请

WO2014167030A1 ANTI-S100A7 ANTIBODIES FOR THE TREATMENT AND DIAGNOSIS OF CANCER 审中-公开
标题翻译：用于治疗和诊断癌症的ANTI-S100A7抗体
公开(公告)号：WO2014167030A1
公开(公告)日：2014-10-16
申请号：PCT/EP2014/057213
申请日：2014-04-09
申请人： ACONDICIONAMIENTO TARRASENSE
发明人： HERNÁNDEZ MÍGUEZ, José Luis , ADAN PLANA, Jaume , MARTÍNEZ ESCOLÀ, Josep Maria , MASA ÁLVAREZ, Marc , MESSEGUER PEYPOCH, Ramon , MITJANS PRAT, Francesc , DAKHEL PLAZA, Sheila , COLL MANZANO, Antonio , HERVAS VILLEGAS, Rosa Mª , CALVIS CALPE, Carme , PADILLA GARCÍA, Laura , ROQUE NAVARRO, Lourdes Tatiana , BARBERÀ FERRANDO, Laura , RIVAS CAÑAS, Manuel
IPC分类号： C07K16/30 , G01N33/53
CPC分类号： C07K16/18 , A61K47/6843 , C07K16/3015 , C07K16/3046 , C07K16/3053 , C07K2317/33 , C07K2317/73 , C07K2317/76 , G01N33/57407 , G01N33/57415 , G01N33/57419 , G01N2333/4727
摘要： The present invention relates to the use of antibodies against S100A7 protein for the prevention and/or treatment of cancer or a disease associated to an undesired angiogenesis or a disease associated with inflammation; and to methods and kits for diagnosing and determining the prognostic of said diseases in vitro and in vivo by means of detecting levels of S100A7 in a biofluid, preferably with an antibody. The invention also relates to specific anti-S100A7 monoclonal antibodies, hybridoma cell lines producing them and method for obtaining them, as well as pharmaceutical compositions and conjugates containing them.
摘要翻译：本发明涉及针对S100A7蛋白的抗体用于预防和/或治疗癌症或与不期望的血管生成或与炎症有关的疾病相关疾病的用途; 以及用于通过检测生物流体中S100A7的水平，优选用抗体来诊断和确定体外和体内所述疾病的预后的方法和试剂盒。本发明还涉及具体的抗S100A7单克隆抗体，产生它们的杂交瘤细胞系和获得它们的方法，以及含有它们的药物组合物和缀合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式